News and Press Releases
Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD
New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthma Lunsekimig now targeting chronic rhinosinusitis and COPD in addition to asthma Itepekimab expanding into chronic rhinosinusitis along with...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 15, 2025
PLL Therapeutics enrolls first patient in phase I/II trial of drug candidate PLL001 for Amyotrophic Lateral Sclerosis (ALS)
Multi-stage Australian study will evaluate safety of PLL001 in 12 ALS patients, testing three different doses along with placebo 140 ALS patients will participate in second stage of study to...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 15, 2025
10 Avenue Roger Lapébie 33140 Villenave d’Ornon France
Eleva Publishes Evidence of Immunomodulation and Neuroprotection Using its Factor H Biological Therapy in Preclinical Dry AMD Study
Eleva confirms dry AMD as second indication for proprietary Factor H (CPV-104) program 15 April 2025 -- Freiburg im Breisgau, Germany -- Eleva, a pioneer in discovering and developing previously...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 15, 2025
Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
Interim blinded safety and pharmacokinetic data to be presented at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) 10 April 2025 -- Maryland, US...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 10, 2025
ESCMID Global 2025: Shionogi presents real-world data demonstrating better clinical outcomes when Fetcroja / Fetroja (cefiderocol) is used as empiric or documented therapy as compared to salvage therapy for the treatment of Gram-negative bacterial infections
Data from five European countries demonstrates the effectiveness of cefiderocol against Gram-negative pathogens considered as high or critical priorities by the WHO, including high rates of clinical cure and day...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 8, 2025
Johnson & Johnson highlights new data, demonstrating long-term sustained disease control in adults living with generalised myasthenia gravis (gMG)
New compelling results demonstrate 18 months of both sustained reduction in immunoglobulin G antibodies and sustained improvement in gMG symptoms in pivotal Vivacity-MG3 study and open label extension phase Up...
Category: Clinical Trials, Other, Pharmaceutical
Posted: April 8, 2025
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch
7 April 2025 -- California, US -- ImmunityBio, Inc, a leading immunotherapy company, today announced details about its Investor Day program to be held on Tuesday, April 15, 2025, at...
Category: Drug Discovery, Other, Pharmaceutical
Posted: April 7, 2025
European Commission approves Johnson & Johnson’s subcutaneous DARZALEX (daratumumab)-based quadruplet regimen for the treatment of patients with newly diagnosed multiple myeloma, regardless of transplant eligibility
Approval cements daratumumab as a foundational therapy in newly diagnosed multiple myeloma and the only anti-CD38 antibody for all patient types in this setting Phase 3 CEPHEUS study shows significant...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 7, 2025
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
European Commission approves subcutaneous RYBREVANT▼ (amivantamab) for the treatment of patients with advanced EGFR-mutated non-small cell lung cancer
Subcutaneous (SC) amivantamab offers patients greater convenience, reducing administration time from hours to minutes and with a five-fold reduction in infusion-related reactions compared to the IV formulation European Commission (EC) approval based on positive...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 7, 2025
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Accure Therapeutics awarded total of $1.6M in grants from The Michael J. Fox Foundation and Fonds National de Recherche de Luxembourg to bring first-in-class drug for Parkinson’s disease to clinical trials
Accure to complete required preclinical studies to file IND application for ACT-02 program in 2026 Fonds National de Recherche (FNR) grant will fund Transcend-PD project, designed to evaluate efficacy of...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 7, 2025
Lundbeck to present positive pipeline data at American Academy of Neurology (AAN) Annual Meeting
4 April 2025 -- Valby, Denmark -- H. Lundbeck A/S (Lundbeck) to present positive interim results from the PACIFIC trial open-label extension investigating bexicaserin, in addition to new analyses from...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 4, 2025
WCG Announces Research Resilience Solutions to Navigate Institutional Budget Constraints
3 April 2025 -- North Carolina, US -- WCG, a global leader in providing solutions that measurably improve and accelerate clinical research, today announced the release of Research Resilience Solutions, a...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 3, 2025
PEPITEM sequence shows effects in psoriasis, comparable to steroid cream
3 April 2025 -- Birmingham, UK -- Birmingham scientists have shown that a sequence of just three amino acids may reduce the severity of psoriasis, when applied topically in an...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: April 3, 2025
Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines
Designation granted for warm autoimmune hemolytic anemia and IgG4-related disease Rilzabrutinib is currently under regulatory review in the US, EU and China for potential use in immune thrombocytopenia. 3 April...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 3, 2025
Astellas and Japanese Foundation for Cancer Research Announce Collaboration to Accelerate Translational and Clinical Oncology Research
Initial collaboration will support projects of mutual interest and help accelerate advancement of Astellas’ early-stage oncology pipeline 2 April 2025 -- Tokyo, Japan -- Astellas Pharma Inc and Japanese Foundation...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 2, 2025
